EA201992583A1 - NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION - Google Patents

NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION

Info

Publication number
EA201992583A1
EA201992583A1 EA201992583A EA201992583A EA201992583A1 EA 201992583 A1 EA201992583 A1 EA 201992583A1 EA 201992583 A EA201992583 A EA 201992583A EA 201992583 A EA201992583 A EA 201992583A EA 201992583 A1 EA201992583 A1 EA 201992583A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
spink2
tcrs
taa
tumor
Prior art date
Application number
EA201992583A
Other languages
Russian (ru)
Inventor
Клаудиа Вагнер
Леони Альтен
Себастьян БУНК
Доминик Маурер
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Priority claimed from PCT/EP2018/067380 external-priority patent/WO2019002444A1/en
Publication of EA201992583A1 publication Critical patent/EA201992583A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к антигенраспознающим структурам к опухолеассоциированным антигенам (ТАА), в частности к ТАА ингибиторам серинпротеаз типа Kazal-2 (SPINK2). В частности, в изобретении предложены новые молекулы на основе Т-клеточного рецептора (ТКР), являющиеся селективными и специфическими к экспрессируемому опухолями антигену по изобретению. ТКР по изобретению и связывающиеся с SPINK2 фрагменты, полученные из этого ТКР, применимы для диагностики, лечения и профилактики раковых заболеваний, при которых экспрессируется антиген SPINK2. Предложены также нуклеиновые кислоты, кодирующие антигенраспознающие структуры по изобретению, векторы, включающие данные нуклеиновые кислоты, рекомбинантные клетки, экспрессирующие эти антигенраспознающие структуры, и фармацевтические композиции, включающие соединения по изобретению.The present invention relates to antigen-recognizing structures for tumor-associated antigens (TAA), in particular to TAA Kazal-2 type serine protease inhibitors (SPINK2). In particular, the invention provides new molecules based on a T-cell receptor (TCR), which are selective and specific for the tumor-expressed antigen of the invention. The TCRs of the invention and SPINK2-binding fragments derived from this TCRs are useful in the diagnosis, treatment and prevention of cancer in which the SPINK2 antigen is expressed. Nucleic acids encoding antigen-recognizing structures according to the invention, vectors including these nucleic acids, recombinant cells expressing these antigen-recognizing structures, and pharmaceutical compositions comprising compounds of the invention are also provided.

EA201992583A 2017-06-30 2018-06-28 NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION EA201992583A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527844P 2017-06-30 2017-06-30
PCT/EP2018/067380 WO2019002444A1 (en) 2017-06-30 2018-06-28 Novel t cell receptors and immune therapy using the same

Publications (1)

Publication Number Publication Date
EA201992583A1 true EA201992583A1 (en) 2020-04-14

Family

ID=70483870

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992583A EA201992583A1 (en) 2017-06-30 2018-06-28 NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201992583A1 (en)

Similar Documents

Publication Publication Date Title
CY1124997T1 (en) NOVEL T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM
CO2020000357A2 (en) Novel T-cell receptors, and immunotherapy using the same
BR112019010972A2 (en) t-cell receptors and immunotherapy using the same
CL2020001181A1 (en) New genetically modified T-cell receptors and immune therapies using them.
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
MX2023003463A (en) T cell receptors and immune therapy using the same against prame positive cancers.
BR112019001922A2 (en) t-cell receptors and immunotherapy using the same
CR20190276A (en) Novel t cell receptors and immune therapy using the same
MX2021011696A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123.
EA201791057A1 (en) ANTIGENSBELTING MOLECULES CONTAINING THERMAL LIGAND OF TNF FAMILIES
EA201791853A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN THE IMMUNOTHERAPY OF CANCER OF THE REFERRAL GLAND AND OTHER TYPES OF CANCER
EA201000207A1 (en) NEW IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY
EA201990321A1 (en) BISPECIFIC ANTI-CURRENT BINDING PROTEINS THAT SPECIFICALLY BIND TO CD3 AND CD123
MX2022007902A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy.
EA201992583A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201390811A1 (en) TOMM34 PEPTIDES AND CONTAINING THEIR VACCINES
EA202090712A1 (en) NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE
EA201991139A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201992002A1 (en) T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION
EA201991151A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201990488A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
CY1124826T1 (en) T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM
CL2019001537A1 (en) New T-cell receptors and immune therapy that uses them.
AR109345A1 (en) T-LYMPHOCYTE AND IMMUNOTHERAPY RECEPTORS BASED ON THE USE OF THE SAME